Insider filing · CADL
Paul Peter Tak
Chief Executive Officer
profile →
Candel Therapeutics, Inc.
CADL · Healthcare · 16 filings in 24 months
ticker →
Paul Peter Tak sold $3.2M of Candel Therapeutics (CADL)
Executed Sep 10, disclosed Sep 11, 1 day later.
Value, as filed
$3.2M
280,245 sh across 2 lots
Executed
Sep 10
the trade date, as filed
Disclosed
Sep 11
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
PTPaul Peter Tak (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Candel Therapeutics, Inc. (CADL). The largest single filing was $3.2M of CADL (280,245 sh across 2 lots, as filed), executed Sep 10.
The name
CADLHealthcare · Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Paul Peter Tak in CADL
CADLSALE
Candel Therapeutics, Inc.
$226K25,772 sh × $8.77
Exec Mar 18 2025
Filed Mar 20 2025 · 5:30 PM ET CADLSALE Candel Therapeutics, Inc. $157K
21,704 sh × $7.23
Exec Jan 15 2025
Filed Jan 17 2025 · 5:30 PM ET CADLSALE Candel Therapeutics, Inc. $174K
21,172 sh × $8.22
Exec Jan 8 2025
Filed Jan 10 2025 · 5:30 PM ET CADLSALE Candel Therapeutics, Inc. $223K
48,847 sh × $4.56
Exec Nov 29 2024
Filed Dec 3 2024 · 5:30 PM ET